Abstract:
The present invention relates to a pharmaceutical composition for preventing or treating neurodegenerative diseases, and a screening method thereof. According to an embodiment of the present invention, by applying the screening method which screens candidate substances for preventing or treating neurodegenerative diseases, a substance for preventing or treating neurodegenerative diseases can be effectively screened. The pharmaceutical composition for preventing or treating neurodegenerative diseases obtained by the screening method can effectively prevents or treats various neurodegenerative diseases.
Abstract:
PURPOSE: A methylidene-heterocyclic compound and a pharmaceutical composition containing the same are provided to strongly suppress IkappaB kinase-b(IKK-b) and to treat various inflammatory diseases. CONSTITUTION: A methylidene-heterocyclic compound is denoted by chemical formula 1. A pharmaceutical composition for preventing and treating inflammatory diseases contains the compound of chemical formula 1 as an active ingredient. The inflammatory diseases include rheumatoid arthritis, juvenile arthritis, asthma, spondyloarthopathies, gout, osteoarthritis, allergic rhinitis, atopic dermatitis, systemic lupuserythematosus, psoriasis, ulcerative colitis, SIRS, sepsis, or polymyositis. A method for preparing the compound of chemical formula 1 comprises: a step of cyclizing an aniline compound of chemical formula 2 and preparing a 3-phenyl rhodanine compound of chemical formula 3; and a step of condensing the compound of chemical formula 3 with aldehyde compound of R2-C(O)H under an acidic condition. [Reference numerals] (AA) Step 1; (BB) Step 2
Abstract:
본 발명은 세로토닌 수용체 억제 작용과 세로토닌 트랜스포터 (Serotonin transporter)에 대한 억제 작용을 동시에 가지는 설폰아마이드 화합물과 이의 약제학적으로 허용 가능한 염에 관한 것이다. 본 발명이 특징으로 하는 설폰아마이드 화합물은 세로토닌 5-HT 2A 수용체 길항 작용과 세로토닌 트랜스포터 억제 작용을 가지므로 우울증, 비만, 정신병(psychosis), 정신분열증, 자살성향(suicidal tendency), 불안증(anxiety), 강박노이로제, 편두통, 식욕부진(appetite disorders), 수면장애(sleep disorders), 발작, 약물남용에 의한 금단증상 등 중추신경계(CNS)에 관련된 질환의 예방 및 치료제로 유용하다. 설폰아마이드 화합물, 세로토닌, 5-HT2A/5-HT2C, SSRI, 중추신경계, 우울증, 비만
Abstract:
PURPOSE: A novel 1,6-disubstituted-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-7-one is provided to suppress cancer cells. CONSTITUTION: A 1,6-disubstituted-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-7-one compound is denoted by chemical formula 1. A pharmaceutical composition for anticancer contains the compound of chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient. A method for preparing the compound of chemical formula 1 comprises a step of alkylating 3-amino compounds of chemical formula 2 with haloalkylcarbonyl piperazine of chemical formula 3 by alkylating.
Abstract:
PURPOSE: A novel 3,6-disubstituted-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-7-one compound is provided to suppress cancer cell and to be used as an anticancer agent. CONSTITUTION: A 3,6-disubstituted-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-7-one is denoted by chemical formula 1. A pharmaceutical composition for anticancer contains the compound of chemical formula 1 as an active ingredient. A method for preparing the compound of chemical formula 1 comprises: a step of performing acrylation of 3-amino compound of chemical formula 2 with acyl halide compound of chemical formula 3 to prepare 3-haloacylcarbamoyl compound of chemical formula 4; and a step of substituting 3-haloacylcarbamoyl compound of chemical formula 4 with amine compounds of chemical formula 5.
Abstract:
본 발명은 하기 화학식 1로 표시되는 신규 페닐아세테이트 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 T-형 칼슘 이온 채널의 활성에 의해 유발되는 질환의 예방 또는 치료용 조성물에 관한 것으로, 본 발명에 따른 페닐아세테이트 유도체를 함유하는 조성물은 T-형 칼슘 이온 채널 활성을 효과적으로 억제하므로 T-형 칼슘 이온 채널의 활성에 의해 유발되는 고혈압, 암, 간질, 신경성 통증 등의 질병의 예방 또는 치료제로서 유용하게 사용될 수 있다. [화학식 1] . (상기 화학식 1에서, 상기 X, R 1 및 R 2 는 본 명세서에서 정의된 바와 같다.) T-형 칼슘 채널 블로커, 페닐아세테이트 유도체, 통증치료제
Abstract:
PURPOSE: A method for preparing 1,6-dioxecane compound is provided to enlarge other ring by Diels-Alder reaction and to use as an intermediate. CONSTITUTION: A 1,6-Dioxecanes compound is denoted by chemical formula 1. The 1,6-Dioxecanes compound is prepared by Prins reaction of alcohol compound of chemical formula 2 and aldehyde compound of chemical formula 3. A tetrahydrofuran is used as a reaction catalyst. The reaction temperature is -78 to 30°C.
Abstract:
PURPOSE: A thiazoline compounds and a T-type calcium channel inhibitor containing the same are provided to treat diseases relating to T-type calcium channel overexpression. CONSTITUTION: A thiazoline compounds have a structure of chemical formula 1. A composition for preventing and treating diseases relating to T-type calcium channel overexpression contains the thiazoline compounds of chemical formula 1. The diseases are Parkinson's disease, Alzheimer, schizophrenia, somnopathy, pain, hypertension, arrhythmia, angina, cardiac insufficiency, myocardial infarction, or cancer.
Abstract:
PURPOSE: A novel phenylacetate derivative and a composition containing the same are provided to suppress T-type calcium ion channel activity and to use as a therapeutic agent for preventing or treating diseases caused by T-type calcium ion channel activity. CONSTITUTION: A phenylacetate derivative is denoted by chemical formula 1. A method for preparing the phenylacetate derivative comprises: a step of performing esterification of a carboxylic acid compound of chemical formula 2 under acid catalyst to obtain an ester compound of chemical formula 3; a step of reacting the compound of chemical formula 3 with t-butoxide and isopropyl bromide to obtain a compound of chemical formula 4; a step of reacting the compound of chemical formula 4 with 1,3-dibromopropane to obtain a compound of chemical formula 5; and a step of reacting the compound of chemical formula 5 with a compound of chemical formula 6 or 7.